<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-23182" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Hyperkalemia</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Simon</surname>
            <given-names>Leslie V.</given-names>
          </name>
          <aff>Mayo Clinic Florida</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hashmi</surname>
            <given-names>Muhammad F.</given-names>
          </name>
          <aff>National Health Service</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Farrell</surname>
            <given-names>Mitchell W.</given-names>
          </name>
          <aff>Indian River State College</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Leslie Simon declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Muhammad Hashmi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mitchell Farrell declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>4</day>
          <month>9</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-23182.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Hyperkalemia is defined as a serum or plasma potassium level above the upper limits of normal, usually greater than 5.0 mEq/L to 5.5 mEq/L. While mild hyperkalemia is usually asymptomatic, high potassium levels may cause life-threatening cardiac arrhythmias, muscle weakness, or paralysis. Symptoms usually develop at higher levels, 6.5 mEq/L to 7 mEq/L, but the rate of change is more important than the numerical value. Patients with chronic hyperkalemia may be asymptomatic at increased levels, while patients with dramatic, acute potassium shifts may develop severe symptoms at lower ones. Infants have higher baseline levels than children and adults. This activity reviews the causes, pathophysiology, and presentation of hyperkalemia and highlights the role of the interprofessional team in its management.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Review the causes of hyperkalemia.</p></list-item><list-item><p>Describe the effects of hyperkalemia on the ECG.</p></list-item><list-item><p>Summarize the treatment options and order of treatment for hyperkalemia.</p></list-item><list-item><p>Outline the importance of improving care coordination among interprofessional team members to improve outcomes for patients affected by hyperkalemia.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23182&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23182">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-23182.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Hyperkalemia is defined as a serum or plasma potassium level above the upper limits of normal, usually greater than 5.0&#x000a0;mEq/L&#x000a0;to 5.5 mEq/L. While mild hyperkalemia is usually asymptomatic, high potassium levels may cause life-threatening cardiac arrhythmias, muscle weakness, or paralysis. Symptoms usually develop at higher levels, 6.5&#x000a0;mEq/L to&#x000a0;7 mEq/L, but the rate of change is more important than the numerical value. Patients with chronic hyperkalemia may be asymptomatic at increased levels, while patients with dramatic, acute potassium shifts may develop severe symptoms at lower ones. Infants have higher baseline levels than children and adults.</p>
        <p>Pseudohyperkalemia is quite common and represents a false elevation in measured potassium due to specimen collection, handling, or other causes. Hyperkalemia should always be confirmed before aggressive treatment in cases where the serum potassium is elevated without explanation. True hyperkalemia may be caused by increased potassium intake, transcellular movement of intracellular potassium into the extracellular space, and decreased renal excretion. The urgency of therapy depends on symptoms, serum levels, and causes of hyperkalemia.<xref ref-type="bibr" rid="article-23182.r1">[1]</xref><xref ref-type="bibr" rid="article-23182.r2">[2]</xref></p>
      </sec>
      <sec id="article-23182.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The most common cause of hyperkalemia is pseudohyperkalemia, which is not reflective of the true serum potassium levels. Pseudohyperkalemia is most commonly due to hemolysis of the sample, causing intracellular potassium to be measured in the serum. Hemolysis is more common when a syringe is used than a vacuum device. Using tourniquets and excessive fist-pumping during the blood draw also increase the risk. Specimens drawn from patients with leukocytosis or thrombocytosis are also frequently associated with falsely elevated potassium concentrations.</p>
        <p>
<bold>Increased Potassium Intake</bold>
</p>
        <p>Increased potassium intake from food is a very uncommon cause of hyperkalemia in adult patients with normal renal function but can be an important cause in those with kidney disease. Foods with high potassium content include dried fruits, seaweed, nuts, molasses, avocados, and Lima beans. Many vegetables that are also high in potassium include spinach, potatoes, tomatoes, broccoli, beets, carrots, and squash. High-potassium-containing fruits include kiwis, mangoes, oranges, bananas, and cantaloupe. Red meats are also rich in potassium. While generally safe to consume even in large quantities by patients with normal potassium homeostasis, these foods should be avoided in patients with severe renal disease or other underlying conditions or medications predisposing them to hyperkalemia. Intravenous intake through high potassium-containing fluids, particularly total parenteral nutrition, medications with high potassium content, and massive blood transfusions can significantly elevate serum potassium levels.</p>
        <p>
<bold>Intracellular Potassium Shifts</bold>
</p>
        <p>Cellular injury can release large quantities of intracellular potassium into the extracellular space. This can be due to rhabdomyolysis from a crush injury, excessive exercise, or other hemolytic processes. Metabolic acidosis may cause intracellular potassium to shift into the extracellular space without red cell injury. Metabolic acidosis is most frequently caused by decreased,&#x000a0;effective circulating arterial blood volume. Sepsis or dehydration may lead to hypotension and decreased tissue perfusion leading to metabolic acidosis with subsequent potassium elevation.</p>
        <p>Insulin deficiency and diabetic ketoacidosis may cause dramatic extracellular shifts causing measured serum potassium to be elevated in the setting of whole-body potassium depletion. Certain medications, such as succinylcholine, may cause severe, acute potassium elevations in patients with up-regulation of receptors, particularly in subacute neuromuscular disease. Tumor lysis syndrome, particularly in patients receiving chemotherapy for hematogenous malignancy, may cause acute hyperkalemia due to massive cancer cell death.<xref ref-type="bibr" rid="article-23182.r3">[3]</xref>&#x000a0;Hyperkalemic periodic paralysis is a rare, autosomal dominant condition that causes potassium to shift into the extracellular space due to impaired sodium channel function in skeletal muscle.</p>
        <p>
<bold>Impaired Potassium Excretion</bold>
</p>
        <p>Acute or chronic kidney disease is a common cause of hyperkalemia. Hyperkalemia is usually not seen until the glomerular filtration rate falls below 30 ml/min. This is commonly due to primary renal dysfunction but may be due to acute volume depletion from dehydration or bleeding or decreased circulating blood volume due to congestive heart failure or cirrhosis. Tubular dysfunction due to aldosterone deficiency or insensitivity can also cause hyperkalemia.</p>
      </sec>
      <sec id="article-23182.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Hyperkalemia is unusual in the general population, reported in less than 5% of the population worldwide, but may affect up to 10% of all hospitalized patients. Most cases in hospitalized patients are due to medications and renal insufficiency. Diabetes, malignancy, extremes of age, and acidosis are other important causes in inpatients. Hyperkalemia is rare in children but may occur in up to 50% of premature infants. Hyperkalemia is more commonly reported in men than women, perhaps due to increased muscle mass and higher rates of rhabdomyolysis, and increased prevalence of the neuromuscular disease. Other factors include&#x000a0;non-Black patients and&#x000a0;older age.<xref ref-type="bibr" rid="article-23182.r4">[4]</xref></p>
        <p>Today there is a risk that empirical use of ACE inhibitors may cause hyperkalemia, which can be of concern in high-risk populations like people with diabetes, heart failure, and peripheral vascular disease.<xref ref-type="bibr" rid="article-23182.r5">[5]</xref></p>
      </sec>
      <sec id="article-23182.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Potassium is usually an intracellular cation. Total body potassium stores are 50 to 75 mEq/kg body weight (approximately 3000 mEq).<xref ref-type="bibr" rid="article-23182.r6">[6]</xref> The sodium-potassium pump is responsible for maintaining potassium within the cells, which pumps sodium out of and potassium into the cell in a 3:2 ratio. This results in approximately 140 mEq/L&#x000a0;intracellular potassium concentration compared with 4 to 5 mEq/L in the extracellular fluid. Most potassium is excreted in urine through the kidneys, with about 10% in sweat and stool. Inside the kidney, potassium excretion occurs in the distal convoluted and cortical collecting ducts.</p>
        <p>Elevated levels of the following influence renal potassium excretion:</p>
        <list list-type="bullet">
          <list-item>
            <p>Aldosterone</p>
          </list-item>
          <list-item>
            <p>Diuretics (which deliver sodium to the distal tubule)</p>
          </list-item>
          <list-item>
            <p>WNK1 and WNK4</p>
          </list-item>
          <list-item>
            <p>High levels of serum potassium</p>
          </list-item>
          <list-item>
            <p>A high flow of urine (osmotic diuresis)</p>
          </list-item>
          <list-item>
            <p>Presence of negative ions in the distal tubule (bicarbonate)</p>
          </list-item>
        </list>
        <table-wrap id="article-23182.table0" position="float" orientation="portrait">
          <table style="height: 205px; width: 691.890625px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr>
                <td style="width: 303px;" rowspan="1" colspan="1">
<bold>Mechanism</bold>
</td>
                <td style="width: 303.890625px;" rowspan="1" colspan="1">
<bold>Causes</bold>
</td>
              </tr>
              <tr>
                <td style="width: 303px;" rowspan="1" colspan="1">
<bold>Increased potassium release from cells</bold>
</td>
                <td style="width: 303.890625px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Pseudohyperkalemia</p></list-item><list-item><p>Metabolic acidosis</p></list-item><list-item><p>Increased tissue catabolism</p></list-item><list-item><p>Beta blockers<xref ref-type="bibr" rid="article-23182.r7">[7]</xref></p></list-item><list-item><p>Insulin deficiency, hyperglycemia, and hyperosmolality</p></list-item><list-item><p>Exercise</p></list-item><list-item><p>Hyperkalemic periodic paralysis</p></list-item><list-item><p>Activators of ATP-dependent potassium channels (e.g., diazoxide, minoxidil, calcineurin inhibitors, and some volatile anesthetics)</p></list-item><list-item><p>Red cell transfusion</p></list-item><list-item><p>Succinylcholine</p></list-item><list-item><p>Red cell transfusion</p></list-item><list-item><p>Arginine hydrochloride</p></list-item></list>
</td>
              </tr>
              <tr>
                <td style="width: 303px;" rowspan="1" colspan="1">
<bold>Reduced urinary potassium excretion</bold>
</td>
                <td style="width: 303.890625px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Reduced aldosterone secretion</p></list-item><list-item><p>Reduced distal sodium and water delivery</p></list-item><list-item><p>Selective impairment in potassium secretion</p></list-item><list-item><p>Ureterojejunostomy</p></list-item><list-item><p>Acute and chronic kidney disease</p></list-item><list-item><p>Gordon syndrome</p></list-item></list>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>
<bold>Table 1. Causes and mechanism of hyperkalemia</bold>
</p>
      </sec>
      <sec id="article-23182.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Most patients are relatively asymptomatic with mild and even moderate hyperkalemia. Elevated potassium is often discovered on screening labs done in patients with nonspecific complaints or those with suspected electrolyte abnormalities due to infection, dehydration, or hypoperfusion. Causes include renal disease, diabetes, chemotherapy, major trauma, crush injury, or muscle pain suggestive of rhabdomyolysis. Medications that may predispose to the development of hyperkalemia include digoxin, potassium-sparing diuretics, non-steroidal anti-inflammatory drugs, ace-inhibitors or recent intravenous (IV) potassium, total parenteral nutrition, potassium penicillin, or succinylcholine. Patients may complain of weakness, fatigue, palpitations, or syncope.</p>
        <p>Physical exam findings may include hypertension and edema in the setting of renal disease. There may also be signs of hypoperfusion. Muscle tenderness may be present in patients with rhabdomyolysis. Jaundice may be seen in patients with hemolytic conditions. Patients may have muscle weakness, flaccid paralysis, or depressed deep tendon reflexes.</p>
      </sec>
      <sec id="article-23182.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The first test that should be ordered in a patient with suspected hyperkalemia is an ECG since the most lethal complication of hyperkalemia is cardiac condition abnormalities which can lead to dysrhythmias and death.</p>
        <p>Elevated potassium causes ECG changes in a dose-dependent manner:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>K = 5.5 to 6.5 mEq/L ECG will show tall, peaked t-waves</p>
          </list-item>
          <list-item>
            <p>K = 6.5 to 7.5 mEq/L ECG will show loss of p-waves</p>
          </list-item>
          <list-item>
            <p>K = 7 to 8 ECG mEq/L will show widening of the QRS complex</p>
          </list-item>
          <list-item>
            <p>K = 8 to 10 mEq/L will produce cardiac arrhythmias, sine wave pattern, and asystole</p>
          </list-item>
        </list>
        <p>It should be noted that the rate of rising serum potassium is a greater factor than the level. Patients with chronic hyperkalemia may have relatively normal EGCs even at high levels, and significant ECG changes may be present at much lower levels in patients with sudden spikes in serum potassium.ECG features of hyperkalemia include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Small or absent P wave</p>
          </list-item>
          <list-item>
            <p>Prolonged PR interval</p>
          </list-item>
          <list-item>
            <p>Augmented R wave</p>
          </list-item>
          <list-item>
            <p>Wide QRS</p>
          </list-item>
          <list-item>
            <p>Peaked T waves</p>
          </list-item>
        </list>
        <p>Additional laboratory testing should include serum blood urea nitrogen and creatinine to assess renal function and urinalysis to screen for renal disease. Urine potassium, sodium, and osmolality may also help evaluate the cause. In patients with renal disease, the serum calcium level should also be checked because hypocalcemia may exacerbate the cardiac effects of hyperkalemia. A complete blood count to screen for leukocytosis or thrombocytosis may also be helpful. Serum glucose and blood gas analysis should be ordered in diabetics and patients with suspected acidosis. Lactate dehydrogenase should be ordered in patients with suspected hemolysis. Creatinine phosphokinases and urine myoglobin should be ordered in patients with suspected rhabdomyolysis. Uric acid and phosphorus should be ordered in patients with suspected tumor lysis syndrome. Digoxin toxicity may cause hyperkalemia, so serum levels should be checked in patients on digoxin. If no other cause is found, consider cortisol and aldosterone levels to assess for mineralocorticoid deficiency.</p>
        <p>Since pseudohyperkalemia is so common, confirmation should be obtained in asymptomatic patients without typical ECG changes before initiating aggressive therapy.</p>
      </sec>
      <sec id="article-23182.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The urgency with which hyperkalemia should be managed depends on how rapidly the condition develops, the absolute serum potassium level, the degree of symptoms, and the cause.<xref ref-type="bibr" rid="article-23182.r8">[8]</xref><xref ref-type="bibr" rid="article-23182.r9">[9]</xref><xref ref-type="bibr" rid="article-23182.r10">[10]</xref></p>
        <p>Patients with neuromuscular weakness, paralysis, or ECG changes and elevated potassium of more than 5.5 mEq/L in patients at risk for ongoing hyperkalemia or confirmed hyperkalemia of 6.5 mEq/L should have aggressive treatment.</p>
        <p>Treatment is usually prescribed in the following manner:</p>
        <list list-type="order">
          <list-item>
            <p>Exogenous sources of potassium should be immediately discontinued.</p>
          </list-item>
          <list-item>
            <p>Treatment of the reversible cause should begin along with the management of hyperkalemia.</p>
          </list-item>
          <list-item>
            <p>Calcium therapy will stabilize the cardiac response to hyperkalemia and should be initiated first in the setting of cardiac toxicity. Calcium does not alter the serum concentration of potassium but is a first-line therapy in hyperkalemia-related arrhythmias and ECG changes. Calcium chloride contains three times more elemental calcium than calcium gluconate but is more irritating to peripheral vessels and more likely to cause tissue necrosis with extravasation, so it is usually only given through central venous lines or peripherally in cardiac arrest. Thus, calcium gluconate is the usual initial drug of choice in patients with evidence of cardiac toxicity.<xref ref-type="bibr" rid="article-23182.r11">[11]</xref> As a precaution, calcium should <bold>never</bold>&#x000a0;be given in bicarbonate-containing fluids, as it can cause the precipitation of calcium carbonate.</p>
          </list-item>
          <list-item>
            <p>Insulin and glucose, or insulin alone in hyperglycemic patients, will drive the potassium back into the cells, effectively lowering serum potassium.<xref ref-type="bibr" rid="article-23182.r12">[12]</xref> A common regimen is ten units of regular insulin given with 50 ml of a 50% dextrose solution (D50). Patients should be monitored closely for the development of hypoglycemia. A 10% dextrose infusion at 50 to 75 ml/hour is associated with less hypoglycemia than bolus dosing with D50.</p>
          </list-item>
          <list-item>
            <p>Beta-2 adrenergic agents such as albuterol will also shift potassium intracellularly.<xref ref-type="bibr" rid="article-23182.r13">[13]</xref>&#x000a0;To be effective, beta-2 agonists are given in much higher doses than those commonly used for bronchodilation. Sodium bicarbonate infusion may be helpful in patients with metabolic acidosis. Bolus dosing of sodium bicarbonate is less effective. Intravenous epinephrine, however,&#x000a0;should <bold>not</bold> be used to manage hyperkalemia due to an increased risk of causing angina.</p>
          </list-item>
          <list-item>
            <p>Loop or thiazide diuretics may help enhance potassium excretion. They may be used in non-oliguric, volume-overloaded patients but should not be used as monotherapy in symptomatic patients. In hypervolemic patients with preserved kidney function (e.g., patients with congestive cardiac&#x000a0;failure), 40 mg of intravenous furosemide is administered&#x000a0;every 12 hours or may be given as a continuous infusion. In euvolemic or hypovolemic patients with preserved kidney function, an isotonic saline infusion is given before as needed to the patient&#x000a0;before administering 40 mg of intravenous furosemide every 12 hours or a continuous furosemide infusion.</p>
          </list-item>
          <list-item>
            <p>Gastrointestinal cation exchangers such as patiromer may be helpful, particularly in patients with renal insufficiency who cannot receive immediate dialysis. Sodium polystyrene sulfonate, though commonly used, is falling out of favor due to lack of effectiveness and adverse effects, particularly bowel necrosis in elderly patients. If used due to a lack of alternatives, it should not be given with sorbitol, which increases toxicity.<xref ref-type="bibr" rid="article-23182.r14">[14]</xref></p>
          </list-item>
          <list-item>
            <p>Hemodialysis should be performed in patients with end-stage renal disease or severe renal impairment.</p>
          </list-item>
        </list>
        <p>Complications of treatment:</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypokalemia</p>
          </list-item>
          <list-item>
            <p>Inability to control hyperkalemia</p>
          </list-item>
          <list-item>
            <p>Hypocalcemia as a result of bicarbonate infusion</p>
          </list-item>
          <list-item>
            <p>Hypoglycemia due to insulin</p>
          </list-item>
          <list-item>
            <p>Metabolic alkalosis from bicarbonate therapy</p>
          </list-item>
          <list-item>
            <p>Volume depletion from diuresis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23182.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Acute tubular necrosis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Congenital adrenal hyperplasia</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Digitalis toxicity</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Electrical burn injuries</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Head trauma</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hypocalcemia</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Metabolic acidosis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Rhabdomyolysis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Thermal burns</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Tumor lysis syndrome<xref ref-type="bibr" rid="article-23182.r3">[3]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23182.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis is excellent for patients with mild transient hyperkalemia if the inciting cause is addressed and treated. Sudden onset, extreme hyperkalemia can cause cardiac arrhythmias that can be lethal in up to two-thirds of cases if not rapidly treated. Hyperkalemia is an independent risk factor for death in hospitalized patients.</p>
      </sec>
      <sec id="article-23182.s11" sec-type="Complications">
        <title>Complications</title>
        <list list-type="bullet">
          <list-item>
            <p>Cardiac arrest</p>
          </list-item>
          <list-item>
            <p>Weakness</p>
          </list-item>
          <list-item>
            <p>Arrhythmias</p>
          </list-item>
          <list-item>
            <p>Paralysis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23182.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Dietary restriction is not usually required, except in extreme cases. Patients with co-morbid conditions or those who take medications causing hyperkalemia should be counseled about urea and electrolytes monitoring as advised by the physician.</p>
      </sec>
      <sec id="article-23182.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The management of hyperkalemia is done by an interprofessional team because of its potential to induce cardiac arrest and severe weakness. Once hyperkalemia is diagnosed, the primary condition must be treated.&#x000a0;Patients with hyperkalemia need cardiac monitoring, and nurses should be familiar with ECG features of hyperkalemia, which are often the first to appear. The pharmacist has to ensure that all nephrotoxic medications and agents that raise potassium are discontinued and discuss their findings with the clinical team. Nursing will perform monitoring and follow-up, watching for signs of worsening hyperkalemia and alerting the clinical staff immediately for corrective action. All interprofessional team members must engage in open communication with the rest of the team, particularly when patient status changes necessitate intervention. Meticulous records are also crucial to proper patient care so that everyone involved operates from the same up-to-date patient data.</p>
        <p>If hyperkalemia is severe, the nephrologist should be consulted. If ECG changes are present, a cardiology consult should be made. Treatment to lower the high potassium should be ongoing. These patients need cardiac monitoring 24/7 until hyperkalemia has resolved. The dietitian should educate the patient on a low potassium diet. For those with renal dysfunction, continued follow-up with a nephrologist is recommended. Only through open communication between members of the interprofessional team can the morbidity of hyperkalemia be avoided.</p>
        <p>
<bold>Outcomes</bold>
</p>
        <p>The majority of patients have an excellent prognosis. However, patients with chronic disorders like end-stage renal failure may require continual blood work to monitor potassium.<xref ref-type="bibr" rid="article-23182.r15">[15]</xref><xref ref-type="bibr" rid="article-23182.r16">[16]</xref>&#x000a0;[Level 5]</p>
      </sec>
      <sec id="article-23182.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23182&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23182">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/hormones-and-body-chemistry/hyperkalemia/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=23182">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/23182/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=23182">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-23182.s15">
        <title>References</title>
        <ref id="article-23182.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lytvyn</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Godoy</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Scholtes</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>van Raalte</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Cherney</surname>
                <given-names>DZ</given-names>
              </name>
            </person-group>
            <article-title>Mineralocorticoid Antagonism and Diabetic Kidney Disease.</article-title>
            <source>Curr Diab Rep</source>
            <year>2019</year>
            <month>Jan</month>
            <day>23</day>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>4</fpage>
            <pub-id pub-id-type="pmid">30673886</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23182.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Flury</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>[The 'Dangerous' ECG].</article-title>
            <source>Praxis (Bern 1994)</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>108</volume>
            <issue>1</issue>
            <fpage>45</fpage>
            <page-range>45-52</page-range>
            <pub-id pub-id-type="pmid">30621532</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23182.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Williams</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Killeen</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Tumor Lysis Syndrome.</article-title>
            <source>Arch Pathol Lab Med</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>143</volume>
            <issue>3</issue>
            <fpage>386</fpage>
            <page-range>386-393</page-range>
            <pub-id pub-id-type="pmid">30499695</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23182.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dunn</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Benton</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Orozco-Torrentera</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Adamson</surname>
                <given-names>RT</given-names>
              </name>
            </person-group>
            <article-title>The burden of hyperkalemia in patients with cardiovascular and renal disease.</article-title>
            <source>Am J Manag Care</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>21</volume>
            <issue>15 Suppl</issue>
            <fpage>s307</fpage>
            <page-range>s307-15</page-range>
            <pub-id pub-id-type="pmid">26788745</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23182.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ohkuma</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Grobbee</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Hamet</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Harrap</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mancia</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Marre</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rodgers</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Woodward</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chalmers</surname>
                <given-names>J</given-names>
              </name>
              <collab>ADVANCE Collaborative Group</collab>
            </person-group>
            <article-title>Short-Term Changes in Serum Potassium and the Risk of Subsequent Vascular Events and Mortality: Results from a Randomized Controlled Trial of ACE Inhibitors.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2022</year>
            <month>Aug</month>
            <volume>17</volume>
            <issue>8</issue>
            <fpage>1139</fpage>
            <page-range>1139-1149</page-range>
            <pub-id pub-id-type="pmid">35896277</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23182.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boddy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Hume</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Weyers</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>The relation of total body potassium to height, weight, and age in normal adults.</article-title>
            <source>J Clin Pathol</source>
            <year>1972</year>
            <month>Jun</month>
            <volume>25</volume>
            <issue>6</issue>
            <fpage>512</fpage>
            <page-range>512-7</page-range>
            <pub-id pub-id-type="pmid">4625433</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23182.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosa</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Silva</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Landsberg</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Rowe</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Epstein</surname>
                <given-names>FH</given-names>
              </name>
            </person-group>
            <article-title>Adrenergic modulation of extrarenal potassium disposal.</article-title>
            <source>N Engl J Med</source>
            <year>1980</year>
            <month>Feb</month>
            <day>21</day>
            <volume>302</volume>
            <issue>8</issue>
            <fpage>431</fpage>
            <page-range>431-4</page-range>
            <pub-id pub-id-type="pmid">6101508</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23182.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Campbell</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Horvath</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>An evidence- and risk-based approach to a harmonized laboratory alert list in Australia and New Zealand.</article-title>
            <source>Clin Chem Lab Med</source>
            <year>2018</year>
            <month>Dec</month>
            <day>19</day>
            <volume>57</volume>
            <issue>1</issue>
            <fpage>89</fpage>
            <page-range>89-94</page-range>
            <pub-id pub-id-type="pmid">29672264</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23182.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Butler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vijayakumar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pitt</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Revisiting hyperkalaemia guidelines: rebuttal.</article-title>
            <source>Eur J Heart Fail</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>20</volume>
            <issue>9</issue>
            <fpage>1255</fpage>
            <pub-id pub-id-type="pmid">30182493</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23182.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Butler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vijayakumar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pitt</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Need to revisit heart failure treatment guidelines for hyperkalaemia management during the use of mineralocorticoid receptor antagonists.</article-title>
            <source>Eur J Heart Fail</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>20</volume>
            <issue>9</issue>
            <fpage>1247</fpage>
            <page-range>1247-1251</page-range>
            <pub-id pub-id-type="pmid">29882618</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23182.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Long</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Warix</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Koyfman</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Controversies in Management of Hyperkalemia.</article-title>
            <source>J Emerg Med</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>55</volume>
            <issue>2</issue>
            <fpage>192</fpage>
            <page-range>192-205</page-range>
            <pub-id pub-id-type="pmid">29731287</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23182.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sterns</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Grieff</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bernstein</surname>
                <given-names>PL</given-names>
              </name>
            </person-group>
            <article-title>Treatment of hyperkalemia: something old, something new.</article-title>
            <source>Kidney Int</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>89</volume>
            <issue>3</issue>
            <fpage>546</fpage>
            <page-range>546-54</page-range>
            <pub-id pub-id-type="pmid">26880451</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23182.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gosmanov</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Thomason</surname>
                <given-names>DB</given-names>
              </name>
            </person-group>
            <article-title>Duality of G protein-coupled mechanisms for beta-adrenergic activation of NKCC activity in skeletal muscle.</article-title>
            <source>Am J Physiol Cell Physiol</source>
            <year>2002</year>
            <month>Oct</month>
            <volume>283</volume>
            <issue>4</issue>
            <fpage>C1025</fpage>
            <page-range>C1025-32</page-range>
            <pub-id pub-id-type="pmid">12225966</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23182.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mistry</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shea</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gigu&#x000e8;re</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of Sodium Polystyrene Sulfonate Dosing Strategies in the Inpatient Management of Hyperkalemia.</article-title>
            <source>Ann Pharmacother</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>50</volume>
            <issue>6</issue>
            <fpage>455</fpage>
            <page-range>455-62</page-range>
            <pub-id pub-id-type="pmid">27048188</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23182.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Formiga</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Chivite</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Corbella</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Conde-Martel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ar&#x000e9;valo-Lorido</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Trull&#x000e0;s</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Silvestre</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Manzano</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Montero-P&#x000e9;rez-Barquero</surname>
                <given-names>M</given-names>
              </name>
              <collab>RICA investigators group</collab>
            </person-group>
            <article-title>Influence of potassium levels on one-year outcomes in elderly patients with acute heart failure.</article-title>
            <source>Eur J Intern Med</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>60</volume>
            <fpage>24</fpage>
            <page-range>24-30</page-range>
            <pub-id pub-id-type="pmid">30722845</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23182.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Linde</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Qin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bakhai</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Furuland</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ayoubkhani</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Palaka</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bennett</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>McEwan</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21&#x000a0;334 patients in the UK.</article-title>
            <source>ESC Heart Fail</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>280</fpage>
            <page-range>280-290</page-range>
            <pub-id pub-id-type="pmid">30629342</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
